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SOMMARIO 
 
La pressione alta aumenta il carico di lavoro cardiaco e causa l'ipertrofia ventricolare sinistra 
(LVH). L’ipertrofia ventricolare sinistra è un importante fattore di rischio per la morbilità e la 
mortalità cardiovascolari. L’ipertrofia ventricolare sinistra è caratterizzata principalmente da 
due diversi fenotipi: (1) un ventricolo sinistro ingrandito a causa dell’aumento dello spessore  
della parete del muscolo cardiaco e (2) un ventricolo sinistro ingrandito a causa dell’aumento 
della dilatazione della parete del muscolo cardiaco. I meccanismi molecolari e patologici con 
i quali si verificanoentrambi  i fenotipi sono  sconosciuti. Inoltre, entrambe le varianti 
fenotipiche dell’ipertrofia ventricolare sinistra sono determinate da cambiamenti quantitativi e 
qualitivi nell'espressione genica di cellule miocardiche che si traducono in alterazioni 
strutturali ed emodinamiche nel miocardio. Pertanto, la genetica gioca un ruolo importante 
nello sviluppo dell’ipertrofia ventricolare sinistra.  
In questo lavoro, abbiamo effettuato uno studio di associazione genome-wide  al fine di  
indagare sulla genetica dell’ ipertrofia ventricolare sinistra (LVH) e dell’indice di massa 
ventricolare sinistra (LVMI). Abbiamo valutato questi tratti in una popolazione di studio di 
1,212 soggetti di origine europea bianca e 2,5 milioni di polimorfismi nucleotidici (SNPs). 
I risultati di questa indagine hanno dato 19 varianti significative (P < 5x10-7), tra cui due 
varianti sul cromosoma 1 nei locus genici di C1orf106 (rs6427864, P = 1.21 x 10-7), e del 
gene MCOLN2 (rs1030932, P = 2.61x10-7), due varianti localizzate vicine al gene IGBP5 
(rs13389579, P = 1.33x10-9) e al gene SP140 (rs4972945, P = 2x10-9), uno sul cromosoma 3 
vicino ZNF717 (rs686591, P = 3.93x10-9), tre sul cromosoma 4 in VEGFG (rs4557213, P = 
9.52x10-11), in GABRB1 (rs728294, P = 1.28x10-8), e in ADH1C (rs283410, P = 2.36x10-8), 
due sul cromosoma 6 nei pressi di un pseudogene piruvato chinasi (rs93992718, P = 
1.15x10-8) e HLA-DRA (rs6911419, P = 2.69x10-7), uno sul cromosoma 7 in VSTM2A 
(rs1403237, P = 4.90x10-10), uno sul cromosoma 8 vicino KCNU1 (rs7464912 , P = 5.97x10-
8), uno sul cromosoma 9 in ABL1 (rs10556171, P = 1.67x10-7), tre sul cromosoma 11 tra 
HEPHL1 e PANX1 (rs4753538, P = 4.19x10-10), in ARHGEF12 (rs11217837, P = 5.54 x10-8), 
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in SLC35C1 (rs7130656, P = 8.71x10-8) e due sul cromosoma 12 vicino KLRA1 
(rs11053849, P = 9.43x10-8 e rs10845156, P = 1.06x10-7). 
I risultati genome-wide dell‘esame LVMI hanno mostrato varianti significative; tuttavia al 
suggestivo valore di P <1x10-5 due regioni potenzialmente suscettibili di 97.6 Kb nel gene 
SYT14 e 3.4 kb nel gene GAS1 sono stati identificati per associazione con LVMI. 
In conclusione, abbiamo identificato 19 regioni suscettibili ad ospitare varianti comuni che 
sono state associate con l’ipertrofia ventricolare sinistra e 2 regioni potenzialmente associate 
con LVMI. Ulteriori studi funzionali genetici sono necessari per caratterizzare la rilevanza 
biologica nell‘ipertrofia indotta da sovraccarico di pressione. 
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ABSTRACT 
 
High blood pressure makes the heart work harder and promotes enlargement of the left 
ventricle, left ventricular hypertrophy (LVH), which is an important risk factor for 
cardiovascular disease and death.  
LVH is characterized for the most part by two different sets of observable 
characteristics (genetic phenotypes): an enlarged left ventricle (1) due to increasing wall 
thickness and (2) due to increasing wall dilation. The molecular and pathological 
mechanisms by which either phenotype occurs is unknown. We do know, however, that both 
phenotypic variations of LVH are determined by quantitative and qualitive changes in the 
genetic expression of cardiac cells that result in structural alterations in the muscular tissue 
that affect the blood flow within the heart. 
Genetics, the study of heredity and the variation of inherited characteristics, therefore 
play a prominent role in the development of LVH. A genome-wide association (GWA) study 
to investigate the genetics of LVH and left ventricular mass index (LVMI) in a cross-sectional-
study of 1,212 subjects of white European ancestry and 2.5 million nucleotide polymorphisms 
(SNPs) yielded a total of 19 genome-wide significant (P < 5x10-7) variants. The GWA 
revealed no genome-wide significant variants; however, at suggestive P value < 1x10-5    
were found  two potentially susceptible regions of 97.6 Kb in the SYT14 gene and 3.4 kb in 
the GAS1 gene for association with LVMI.  
Nineteen (19) susceptible regions harboring common variants associated with LVH 
and 2 potential regions associated with LVMI were found. Further functional genetic studies 
(relating to a variable quantity whose value depends on one or more other variables) are 
required to characterize the biological relevance of these findings to high blood pressure 
associated with enlargement of the left ventricle. 
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INTRODUCTION 
 
Blood pressure 
Blood pressure (BP) measured in millimeters of mercury (mmHg) is defined as forced 
exerted by the blood against unit area of the vessel wall. In hemodymic terms, blood 
pressure is described as: 
 
BP ≅ CO x SVR mmHg 
 
BP is generated by the left ventricle ejecting oxygenated blood through the aortic valve into 
the aorta and into the systemic vasculature, which acts as a resistance to cardiac output. 
These series of events are actually described by the following equation: 
 
CO = SV x HR liters/minute, 
 
where CO, cardiac output; SV, stroke volume;  and HR, heart rate;  
Ejection of the blood into the aorta is characterized by two pressure measures occurring at 
different instants of time, the highest pressure called systolic pressure (Psystolic) and the 
lowest pressure called diastolic pressure (Pdiastolic), as shown in Figure 1. The difference 
between these two pressures is called pulse pressure (PP), defined as 
 
    PP = Psystolic - Pdiastolic  mmHg, 
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Figure 1. Arterial blood pressure wave 
 
 
 
The mean pressure is estimated by the mean arterial pressure (MAP), defined as 
 
    MAP ≅ 1/3 x (Psystolic - 2 x Pdiastolic) mmHg 
 
As blood flows down from the aorta through the systemic vasculature, changes in the 
diameters of the arterial bed, which serve to regulate blood perfusion into the organs, are 
encountered. These changes in arterial vessel diameters are known as systemic vascular 
resistance. Thus, the factors that determine the actual mean arterial pressure are cardiac 
output (CO), systemic vascular resistance (SVR), and the central venous pressure (CVP), as 
given in the following equation: 
 
    MAP = (CO x SVR) + CVP mmHg 
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From this equation, it is easily to see that a change in the mean arterial pressure is 
dependent on a change in any of the determinants on the right side of the equation. (Note 
that since CVP ranges from 3 - 8 mmHg, for practical MAP calculation CVP is considered 0 
mmHg). A graphical representation of the mean arterial pressure within the systemic 
circulation is illustrated in Figure 2.  
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Figure 2. MAP within the systemic circulation 
 
 
Hypertension 
Hypertension, or high blood pressure (elevated arterial blood pressure), defined as systolic 
BP ≥140 mmHg and/or diastolic BP ≥ 90 mmHg, is the most common risk factor of 
cardiovascular disease. It is the major cause of heart attacks (cardiovascular mortality), 
stroke, and end-stage renal disease. 
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 Hypertension is a quantitative disease wherein the distribution of blood pressure is 
continuous, becoming skewed at high levels. Frequently it is classified clinically by three 
mechanisms: by its severity (i.e., blood pressure elevation), by its underlying cause (i.e., 
primary or essential hypertension vs. secondary hypertension), and by its prevalence in an 
aging population.  
 
Prevalence of hypertension 
Hypertension is highly prevalent everywhere, affecting more than 600 million people and 
accounting for 6 % of adult deaths  worldwide1. In Italy, hypertension is a common medical 
disorder, with 37.7% of the population suffering from the disease2.  
 Unlike tropical and infectious diseases where prevalence and incidence are well 
documented by epidemiologic and demographic studies, in hypertension these 
epidemiological an demographic measures are inconsistent across geographical regions, 
mostly because of variations attributed to differences in economic development and social 
and cultural determinants at the local level3. Other determinants, such as lack of 
standardized measurement, variability in drug treatment, confounding effects of aging, and 
intrinsic (genetic) factors for the disease, also contribute to changes in hypertension in 
various populations.   
 
Hypertension and aging  
The structural changes of the heart are inevitable as cardiac cells age and contractile forces 
debilitate, causing apoptosis and necrosis to occur.  The mechanisms that regulate blood 
pressure work differently in the young and middle-aged (age 20–59 years) and in the old 
(age ≥ 60 years), resulting in various cardiac structural changes and the flow of blood 
(hemodynamic changes) within the heart4, 5.  
 The hemodynamics of blood pressure are not linearly correlated with increasing age.  
While elevated systolic blood pressure is a persistent risk factor for cardiovascular disease in 
subjects younger than 50 years of age, diastolic blood pressure is a stronger predictor, and 
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in subjects older than 60 years of age pulse pressure becomes a better predictor since 
diastolic blood pressure is inversely associated with cardiovascular disease in older persons.  
In the geriatric population, hypertensive subjects, especially those whose arteries fail to 
distend in response to applied pressure (due to hardening of the arteries, or arteriosclerosis), 
systolic blood pressure tends to increase (with little or no effect on diastolic blood pressure). 
 In all persons, with the exception of the obese, the pattern of blood flow in the heart, 
while maintaining normal cardiac output, changes under high blood pressure, increasing total 
peripheral resistance.  
   
Hypertension and other risk factors 
Risk factors, such as obesity, a sedentary lifestyle, the excessive consumption of alcohol, 
excessive use of salt, and low potassium intake, profoundly affect to the manner of 
development (pathogenesis) of hypertension; however, how these risk factors are involved in 
the molecular changes of the heart has yet to be determined. 
 
Molecular and cellular biology of hypertension 
The molecular and cellular biology of high blood pressure requires an understanding of 
phenotypes, polygenes, and common variants. A phenotype consists of the set of observable 
characteristics of an individual resulting from the interaction of its genotype with the 
environment. A polygene is a gene whose individual effect on a phenotype is too small to be 
observed, but which can act together with others to produce observable variation. A common 
variant is a common allele that is unchanged across human populations. Common variants 
can be classified either as a disease-causing allele (also known as causal variant) or non-
causal allele whose function is not yet determined. A causal variant is found in the coding or 
regulatory sequence of a gene or between genes, and it has an effect on protein structure 
and function. A non-causal variant is found in the non-coding region of a gene or between 
genes, and it has no effect in the pathway of the disease.   
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Like most common diseases, hypertension is a complex, polygenic disease with a number of 
causes, or sets of causes (etiologies), interacting to produce complex phenotypes. 
 In a given population, it is believed (1) that 40-50 % of variance in blood pressure is 
from genetic and environmental factors, (2) that 30-35 % is from heritable genetic factors6-8, 
and (3) that 10 % is from Mendelian forms of hypertension9-14. As for the Mendelian forms of 
hypertension, although many studies have been done that have identified mutations 
underlying various monogenetic (descended from a single pair of ancestors) forms of 
hypertension, these are rare in the general population, thus leaving 90 % of the genetic 
variants still undetermined.  
 The disordered physiological processes (pathophysiological) associated with high 
blood pressure during the systolic phase, diastolic phase, or both, are still unknown. 
The multifactorial etiology of hypertension results from multiple gene interactions working 
together or independently at many different cellular levels. Such interactions are known as 
gene-gene interactions, and because of environmental influences that are likely to induce 
modification resulting from external rather than genetic influences, these epigenetic changes 
affecting DNA transcripts are known as gene-environment interactions.  
Advanced genetic technology has advanced our understanding of the genes involved 
in regulating blood pressure. But to date what thus technology has revealed is only a part of 
the wide range of genetic architecture involved in the study of high blood pressure.  
 
Diseases caused by high blood pressure 
Of the diseases caused or greatly augmented by high blood pressure, three in particular are 
notable: 
 
 Stroke:  Hypertension is the most important modifiable risk factor of stroke and 
stroke mortality in adults. Hypertension is characterized by microaneursyms, 
lipohyalinosis, and fibroid necrosis of the penetrating arteries that supply oxygenated 
blood to various parts of the brain, including the basal ganglia, the cerebral deep 
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white matter, and the pons15. Thus, stroke (also known as brain attack) is a 
neurological deficit caused by disrupt disturbance of blood flow in the brain. Stroke is 
the leading cause of death and disability in western societies. There are two types of 
stroke, ischemic and hemorrhagic. And in hypertensive subjects, ischemic stroke 
accounts for 80% of all strokes while the remaining percent is caused by the 
hemorrhagic type16. Severe hypertension is a common feature of subarachnoid 
hemorrhage17.  
 
• End-stage renal disease: Hypertension and diabetes mellitus are the two leading 
causes of end-stage renal disease (ESRD). Hypertension is in fact both a 
consequence and a cause of ESRD18. End-stage renal disease also known as 
chronic renal function (CRF) is defined as complete or almost-complete failure of the 
kidneys to function. The main function of the kidney is to remove waste and excess 
water from the body, while maintaining stable homeostatic functions.    
 
• Chronic heart failure: Hypertension is an important cause of chronic heart failure. 
Chronic heart failure (CHF) often called heart failure (HF) is defined as a 
pathophysiological state in which the heart fails to pump blood and support 
physiological circulation. Mean survival after diagnosis of CHF without treatment is 
1.4 years in men and 2.5 years in women as reported by the Framingham study19.  
 Heart failure is a complex disease that involves many pathological 
mechanisms that lead to malfunction of cardiac muscle and impaired physiology. 
Currently, six pathological causes can lead to heart failure: 
1. Abnormality of the myocardium due to  
a. Myocardial infarction (MI), an irreversible condition that causes the death of 
cardiac muscle (necrosis of heart cells) because of lack of blood supply; 
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b. Left bundle-branch block (LBBB), a condition that causes uncoordinated 
contraction because of delay or obstruction of cardiac impulses propagating 
from the bundle of His to the left bundle branch; 
c. Cardiotoxicity, a condition that impairs electrophysiological and mechanical 
cardiac functions caused by alcoholism, adverse effects of chemotherapy, 
and drug toxicity, developing eventually into cardiomyopathy;    
d. Cardiomyopathy, a condition characterized by injury of heart muscle making 
the heart larger and weaker. This condition is manifested in three forms: 
dilated, hypertrophic, and restrictive;   
e. Hypertrophy, a condition where enlargement of cardiomyocytes (thickening 
of the myocardium) occurs to support cardiac function as to meet body 
tissue demands. Hypertrophic causes decrease the size of the heart 
chambers, including the right and left ventricles; 
2. External work overload, a condition resulting from long-standing or severe 
hypertension. As demonstrated by the Framingham Heart study, 
hypertension accounts for 65 – 85 % of heart failure cases. Heart failure can 
develop in hypertensive patients with either reduced left ventricular systolic 
function or with preserved systolic function and diastolic relaxation 
abnormalities; 
3. Valve abnormalities, a condition involving the dysfunction of one or more 
valves of the heart (i.e., the tricuspid or pulmonary valve on the right-side of 
the heart, or the mitral or aortic valve on the left-side of the heart)   
4. Arrhythmias, a condition where the heart rate is irregular due to problems in 
the heart’s electrical conduction system; 
5. Presence of pericardial abnormalities or a pericardial effusion (tamponade) 
6. Congenital deformities of the heart, a condition caused by developmental 
cardiac malformations during embryogenesis or later in life. It is of 
heterogeneous  etiology associated with mechanical and/or electrical 
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dysfunction of the myocardium20. Genes and environmental influences 
account for 10% of cases of congenital heart disease; however, 
understanding of probable genetic links is increasing. 
 Heart failure results from a combination of two of more causes of heart 
disease that occur asynchronously, simultaneously, or in sequence at different points 
in life. This makes it difficult to define the cause of heart failure to a single form of 
heart disease.  
 For example, long-standing or severe hypertension may lead to structural 
heart disease and cardiac failure through at least two pathways: (1) the development 
of left ventricular hypertrophy and/or left ventricular dilation accompanied by 
abnormal contractility (systolic) or relaxation (diastolic), and (2) myocardial infarction 
resulting in a wall motion abnormality. Either pathway is a sequence of events that 
lead to impaired cardiac function resulting in failure of the heart to pump blood to 
meet the needs of the body.     
 
Left ventricular hypertrophy  
Left ventricular hypertrophy (LVH) is a common manifestation of hypertension that is life 
threatening if left untreated. LVH manifests itself in increased left ventricular mass (LVM) and 
is a powerful predictor of morbidity and mortality. Subjects with untreated LVH are at 
increased risks for coronary heart disease, stroke, congestive heart failure, and sudden 
death. 
 LVH occurs either from a response to long pressure overload that increases the left 
ventricular (LV) wall thickness (concentric LVH, as in hypertrophic cardiomyopathy) or from a 
response to chronic volume overload that promotes LV dilation (eccentric LVH, as in dilation 
cardiomyopathy). In both responses, myocardial muscle mass increases due to enlargement 
of cardiomyocytes and changes in individual myofibrils. 
 Left ventricular concentric hypertrophy is described by an increase in the left 
ventricular wall thickness in response to long-standing pressure overload to normalize left 
 19 
ventricle wall tension. Under this condition, the weight of the heart increases 
disproportionately, increasing the overall cardiac size. By Laplace’s law, this phenomenon 
can be described as: 
   Wall tension = (Pressure x LV radius) / (LV wall thickness), 
 
where LV, left ventricle. The left ventricular wall thickness may exceed 2 cm and the heart 
weight may exceed 500 g. 
Concentric hypertrophy tends to occur because of hypertension or aortic stenosis and it is 
associated with normal or reduced left ventricular end-diastolic volume (LVEDV). With time, 
the thickened left ventricular wall shifts to stiffness leading to dysfunctional diastolic filling.  
 LVH caused by long-standing or severe hypertension is an independent predictor of 
mortality and a well-known established precursor of heart failure, myocardial infarction, and 
stroke. Population studies indicate that each 50 g/m2 increase in left ventricular mass (LVM) 
correlates to a factor increase of 1.7 in sudden death21; However, a much recent study 
reported that every 39 g/m2  increase in LVM confers to a 40% increase in risk of 
cardiovascular events, particularly in hypertensive subjects22. 
 Progression from LVH to heart failure is associated with LVH (either eccentric,  
concentric, or a mixture of the two), ischemia, increase fibrosis and ventricular stiffness, 
necrosis, apoptosis, and systolic ventricular failure.  
 
Diagnosis of left ventricular hypertrophy  
Left ventricular hypertrophy (LVH) diagnosis can be performed by: electrocardiogram, 
echocardiogram, and cardiac magnetic resonance imaging. 
 ECG-defined LVH is a low-cost and easy diagnostic test commonly perform during 
periodic examinations; however, its sensitivity and specificity are < 50 % and >90 %, 
respectively. ECG testing captures a wide variety of voltage abnormalities, which may not be 
necessarily correlated with LVH, thus making the assessment for LVH unreliable for persons 
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who do not meet all the ECG-LVH criteria. The general ECG features for assessing presence 
of LVH include: 
 ≥ QRS amplitude (voltage criteria) 
 Prolongation of the depolarization (delayed intrinsicoid deflection) 
 Widened QRS / T angle (signal pattern criteria)  
 Leftward shift in frontal plate QRS axis (ST-T abnormality criteria) 
 Evidence of atrial enlargement (LAE) 
ECG-LVH characterized by voltage alone underestimates the risk of adverse cardiovascular 
outcomes of left ventricular hypertrophy with or without repolarization abnormalities. 
Moreover, the exact mechanism of the voltage increase is not clear.  
 Echo-defined LVH is a much more sophisticated and accurate diagnostic test; 
however, it is more costly than ECG. Echo-LVH measures the geometric and blood flow 
patterns in the heart using ultrasound technology. Specifically, it offers the opportunity to 
calculate true left ventricular volumes, to estimate LV overall size and performance, and to 
evaluate systolic and diastolic functions in time. This is an improved method for assessing 
presence of LVH with sensitivity of 70 – 90 %.   
 Approximately 20% of heart failure cases are attributed to ECG-LVH diagnoses, 
whereas 60 – 70 % to Echo-LVH.  
 MIR-LVH is an optimum method for evaluating cardiac chamber and vessel anatomy 
as well as for determining functions and structures of the cardiovascular system using high 
quality imaging techniques. This diagnostic tool is an expensive modality for assessment of 
LVH and it is not always available in clinical settings and to every patient, making its usage 
limited.  
 
Molecular mechanisms of left ventricular hypertrophy  
The molecular mechanisms involved in the pathogenesis of LVH, which include increasing 
muscular, vascular, and collagenous components of the myocardium, are not known.  
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LVH is a multifactorial process influenced by a complex interplay of genetic, environmental, 
hemodynamic, and neurohumoral factors as well as demographic factors (e.g., age, gender, 
race), comorbid diseases (e.g., obesity, diabetes mellitus, coronary artery disease), and 
coincident pharmacologic therapies23.   
 LVH is associated with structural and molecular mechanisms far distinct from 
physiological left ventricle hypertrophy and compensatory cardiac remodeling24.  
Under pressure overload conditions, both neurohumoral and mechanical stimuli activate 
various protein processes  leading to the activation of several signaling molecules (e.g., 
calcium dependent proteins, protein kinases, and intracrine growth factors 25, 26) and to the 
involvement of many transcription factors 27, 28. 
 
Monogenic versus polygenic phenotypes of LVH  
Monogenic phenotypes of left ventricular hypertrophy result from genetic mutations of 
Mendelian forms (i.e., rare mutation of single genes), including a variety of missense 
mutations encoding sarcomeric proteins (e.g., beta-myosin heavy chain, myosin-binding 
protein C, troponin T and I, titin, and alpha-actin, to name a few), mutations encoding 
nonsarcomeric proteins (e.g., PRKAG2, LAMP-2), and mutations  encoding mitochondrial 
proteins 29.    
Polygenic phenotypes of left ventricular hypertrophy results from a combination of multiple 
genes and environmental factors. However, it is very likely that each of the genes involved in 
the development of LVH provides a small contribution (i.e., genetic additive effect) to the 
overall phenotype. Such additive effects are either amplified or masqueraded when 
combined with environmental factors.  
 
Heritability of LVH 
Genetic factors account for up to 60% of variance of LV mass30-36, and the remaining 40% is 
explained by conventional factors, such as age, gender, blood pressure, and body mass 
index. 
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Family history of LVH 
Family history of cardiac hypertrophy is an important index for quantifying familial 
susceptibility to the disease, in particular for monogenic forms of LVH. For polygenic forms of 
LVH as the one induced by hypertension, family history of high blood pressure precedes 
familiarity of LVH since it carriers a 2-fold risk in first-degree relatives.  
 
 
Genetics of LVH 
An increasing number of single nucleotide polymorphisms in genes that contribute to the 
development of cardiac remodeling and variation of LV mass have been identified, such  
angiotensin converting enzyme (ACE)37-39, peroxisome proliferator-activated receptor alpha 
(PPARA)40, guanine nucleotide binding G protein beta polypeptide 3 (GNB3)41, and 
cytochrome P450 family 11 subfamily B polypeptide (CYP11B2)42. Other genetic loci that 
have been association with LVH include cardiotrophin-1 (CT-1)43, ryanodine receptor 1 
(RYR1)44, and neural cell adhesion molecule 1 (NCAM1)45. 
 
Fundamental concepts 
Genetics 
From studies in human genetic architecture, it is known that on average, any two individuals 
share more than 99.5 % of their DNA sequences. The remarkable diversity of humans is 
encoded in less than 0.5 % of DNA, approximately 15 million base pairs. It is within this 
range that variations in disease predisposition and response to environmental factors reside. 
 Moreover, DNA variations are determined by two common forms, single-nucleotide 
polymorphisms (SNPs) and copy number variations (CNVs), both of which can occur 
anywhere in the genome. In particular, SNPs may occur throughout the genome (e.g., in 
exons, introns, intergenic, or regulatory regions) at a frequency of approximately one 
nucleotide in every stretch of about 1000 base pairs. However, only 1 % of SNPs occur in 
coding regions, and therefore variations of these coding sequences could alter the gene 
product and susceptibility to a phenotypic difference or to a disease.  
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 SNPs serve both as a physical landmark within the genome and as a genetic marker 
whose transmission can be followed in a family pedigree. Also, because of their prevalence 
and nonrandom distribution throughout the genome, SNPs can be used in linkage analysis 
for identifying haplotypes associated with disease.  
 CNVs, on the other hand, are genetic variations consisting of large contiguous 
stretches of DNA, ranging from 1000 to millions of base pairs. CNVs alike SNPs, but in 
complex rearrangements of genomic material and with multiple alleles, can be present or 
missing in a given population, thereby causing genotypic and phenotypic differences among 
human populations.  
 From monogenic studies, it is known that mutations caused by single base pair 
substitutions or insertion/deletions (frameshift) can lead to dramatic changes on the 
organism. Mutations that occur in exonic regions alter all or part of the amino acid sequence, 
thus causing detrimental effects on the organism. However, there are more variations outside 
the exonic regions than within; therefore, there is a greater need for investigating these 
regions and the role that they play in the onset of a disease. Additionally, thoughtful 
investigation of such gene products as encoded proteins, transcription factors, promoter 
regions, and microRNAs, as well as associated regulatory functions, is also necessary to 
complete the genetic spectrum of the disease.  
 
Phenotype 
Studying well-defined phenotypes (or traits) of complex diseases can make the outcome of 
the study more homogenous, as it focuses on a specific pathophysiological pathway. 
Defining a phenotype, enable us to study the genetic epidemiology of complex disease as a 
discrete or quantitative trait. However, defining a well-definite phenotype for a disease is a 
challenging task, since there is phenotypic heterogeneity, that is,  for the same disease (or 
trait), different features are manifested among related individuals or within a homogenous 
population.  
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Genetic epidemiology 
Genetic epidemiology is the study of genes, environmental factors, and their joint effects 
concerning the pathogenesis of a disease within and across populations.  
Genetic epidemiology was defined by Morton NE, 1982 as “a science which deals with the 
etiology, distribution, and control of disease in groups of relatives and with inherited causes 
of disease in populations”.  
Studying genetic epidemiology of a complex disease is a challenging task, since many genes 
and environmental factors play a role and it is difficult to quantify all factors accounting for the 
disease. On the other hand, studying plausible factors that are related to the disease, 
although it only accounts for a small risk, broadens our knowledge about the course of the 
development of disease.  
 
Working together with genotypes and phenotypes in a population, it is possible to study the 
genetic epidemiology of a disease as it is illustrated in Figure 3  
Gene            Protein         PHENOTYPE
(or Trait)
GENOTYPE
 
Figure 3. Genetic epidemiology framework 
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Gene discovery approaches 
The objective of gene discovery testing is being able to predict the phenotype (or trait) based 
on genotypic and environmental information. Genetic discovery testing is an approach to (1) 
provide new knowledge regarding the etiology and molecular mechanisms in the 
pathogenesis of a disease, (2) contribute to advanced development of novel treatments (e.g., 
personalized medicine), (3) identify people at risk, and (4) implement early diagnosis and   
prevention treatment measures.  
 To pursue unconventional gene discovery for complex diseases, genome-wide 
association studies (GWAS) (examination of thousands of SNPs across the genome) or 
candidate gene studies (examination of certain number of SNPs at a genomic location of 
interest) need to be conducted in a population, consisting of a large number of individuals 
with and without the disease. Particularly, a population study can be based on a cross-
sectional or case-control study design. Having a large sample size, guarantees enough 
statistical power to detect genetic variants (particularly common variants with allele frequency 
greater than 10%) associated with the trait or disease of interest.  
 GWAS and candidate gene studies are powerful methods of identifying genetic 
variants that are associated with an increased risk of developing the disease. Such variants 
themselves may be causative or may be in linkage disequilibrium (LD) with other genetic 
variants that are located in the vicinity and of which are responsible for the increased risk.  
 
In a population, genotypes of individuals are compared (usually under and additive model) as 
illustrated in Figure 4. 
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Study
Population
Genotypes for SNP
in study population
Under an additive model:
aa = 0
Aa = 1
AA = 2
 
Figure 4. Association analysis of a SNP in a population 
  
 
Currently, there are various genetic approaches, including 
 
- Genome-wide linkage analysis 
A genome-wide linkage approach examines the whole genome in a hypothesis-free 
approach with a limited number of genetic markers (about few hundreds) in 
populations of related individuals (based on family-based study disease) to identify 
regions of the genome that contain genes possibly predisposing to the disease or a 
trait of interest. 
 GWA linkage analysis is based on the principle that loci that are close 
together, segregate together more often than loci that are further apart, as 
chromosomal recombination will occur more frequent between distance loci with a 
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probability of 0.5. The rationale of linkage is that deviation from this probability 
indicates linkage between the disease and the genetic locus.  
This technique has been successful at the identification of the genetic 
variation underlying single-gene (monogenic/Mendelian) disorders, but not very 
successful for multifactorial diseases or traits.  
The advantage of linkage studies is that they are powerful for traits explained by rare 
variants with large effects.  
 
- Candidate gene analysis 
A candidate gene analysis examines variants in a particular gene whose function is 
suspected to be involved in the pathogenesis of the disease of interest. Therefore, a 
hypothesis regarding the gene involvement in the development of the disease is 
adopted prior to analysis. Candidate gene analysis is performed in a population-
based setting for association of one or more variants in the gene with the trait and/or 
phenotype of interest. In a candidate gene analysis, one or more genes can be 
analyzed given a priori hypothesis.  
The disadvantage of this approach is that suffers from lack of replication in 
independent large-scale studies. 
 
- Genome-wide association analysis 
A genome-wide association (GWA) analysis examines dense maps of single 
nucleotide polymorphism (SNP) makers in a hypothesis-free manner, that is, without 
making any assumption of genes involved in the pathogenesis of the disease (or trait) 
of interest.  
The feasibility of performing a genome-wide association analysis have been 
due to the availability of rapid advancement in the field of array genotyping 
technology and of the completion of the reference sequence of the human genome 
project and the International HapMap project.  
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GWA examines the full genome (determined by the number of markers according to 
the genotyping technology) with the aim of detecting genetic variants in multifactorial 
diseases and related-traits by comparing genoytpes of thousands of individuals in a a 
population or across populations. 
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AIM OF THE PROJECT 
 
Genetic architecture, nucleotide, and polymorphism are terms use in genetics. Genetic 
architecture is the complex genetic structure of something, in the present case heart tissue 
manifesting enlargement of the left ventricle. Nucleotides form the basic structural unit of 
nucleic acids, such as DNA. And polymorphism refers to the presence of genetic variation 
within a population, upon which natural selection can operate. 
 The goal of this project was to determine the genetic architecture of the left ventricular 
hypertrophy (LVH) and left ventricular mass (LVM) in a cross-sectional-study of 1,212 
subjects of white European ancestry (Italian) and 2.5 million nucleotide polymorphisms 
(SNPs), performing a genome-wide association analysis on these traits. 
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MATERIAL AND METHODS 
 
Study population 
The population of this study was selected from the Campania Salute (CS) project, a network 
involving 12,000 outpatients, 23 hospital-based outpatient hypertensive clinics in different 
regional hospitals, and 60 randomly selected general practitioners allocated in the regional 
area, with the Hypertension Clinic of the Federico II University in Naples serving as the 
coordinating center. Further details of this cohort have been previously reported elsewhere46. 
Seven hundred and fifty-four (754) patients for whom echocardiography data was available 
were selected for the study. Additionally, 480 subjects with normal left ventricular (LV) mass 
and without cardiovascular disease were selected from the AVIS Blood Bank in Naples. The 
total final population of the study consisted of 1,212 subjects.  
Participants were referred by their GPs to the coordinating center for evaluation of 
hypertension. Entry examination included ECG, blood and urine biochemistry, 
echocardiography, carotid ultrasound examination, and further examinations, if needed, with 
follow-up examination performed at least once a year. Prevalence of cardiovascular disease 
was defined as a history of previous myocardial infarction, angina, or procedures of coronary 
revascularization, stroke or transitory ischemic attack, congestive heart failure, or chronic 
kidney disease (with >grade 3 and GFR<30 ml/min per 1.73m2) at the time of the first 
examination in the outpatient clinic.  
The traditional risk factors for cardiovascular disease include: (1) diabetes mellitus, 
defined as treatment with insulin or oral hypoglycemic drugs, or as elevated (>126 mg/dL or 
7.0 mmol/L) levels of fasting, non-stressed blood glucose on at least two separate occasions 
in conjunction with adhering to ongoing dietary measures to control glucose level; (2) 
smoking status; (3) family history of myocardial infarction before age 60 years; (4) systemic 
hypertension, defined as a >140 mm Hg systolic or a diastolic blood pressure ≥90 mm Hg 
and/or ongoing pharmacological treatment; (5) hypercholestolemia, defined as total 
cholesterol >200 mg/dL (or 5.17 mmol/L) and/or LDL-cholesterol > 100 mg/dL (or 2.58 
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mmol/L); (6) hypertrygliceridemia, defined as ≥150 mg/dL; chronic kidney disease, defined as 
estimated glomerular filtration rate (eGFR) <60 ml/min/1.73 m2; (7) metabolic syndrome, 
defined according to the NCEP ATP III criteria, i.e., if three or more of the following five 
criteria are met: waist circumference over 40 inches (men) or 35 inches (women), blood 
pressure over 130/85 mmHg, fasting triglyceride (TG) level over 150 mg/dl, fasting high-
density lipoprotein (HDL) cholesterol level less than 40 mg/dl (men) or 50 mg/dl (women) and 
fasting blood sugar over 100 mg/dl. 
Left ventricular mass was calculated using the Devereux equation47 in accordance 
with the American Society of Echocardiography (ASE) criteria48 defined as follows:  
 
LV mass = 0.8 x (1.04 x [(IVS+LVDD+PWT)3 – (LVDD)3]) + 0.6 grams,  
 
where IVS is interventricular septal thickness in cm, LVDD is left ventricular diastolic 
diameter, and PWT is left ventricular posterior wall thickness in cm.  
The LV mass was indexed by body surface area using normal limits from the Framingham 
Heart study (FHS). Left ventricular hypertrophy was defined by left ventricular mass index 
>116 g/m2 in men and >104 g/m2 in women as suggested in the FHS21.  
 
The study's protocol was approved by the Medical Ethics Review Board of the Federico II 
University in Naples. All participants provided informed consent.  
 
Sample collection 
During the regular routing examination, a blood sample (5 ml) was drawn from each 
participant enrolled in the study and was collected into EDTA tubes. All participants 
completed an interview that contained information about demographic and phenotypic data 
as aforementioned.  
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Genotyping 
Genomic DNA from peripheral blood leukocytes was extracted using a commercially 
available kit (DNA Qiamp Midi kit (QIAGEN). This was performed at Scientific and 
Technological Park IRCCS Multimedica, Milan, Italy.  
DNA samples were then processed according to standard Illumina protocol and were 
genotyped on Illumina SNP array.  
 The Italian study was genotyped in two stages. In the first stage, 727 subjects were 
genotyped on the Illumina InfiniumTM II HumanHap300 Genotyping BeadChips v.2.0 (with 
318,237 markers). In the second stage, 698 subjects were genotyped on the Illumina 
HumanOmni1-Quad BeadChip (with 1,140,419 markers) 
 Quality control for genotypes was determined using the Illumina-provided standard 
definition cluster-file for the HumanHap300 v.2.0 and the HummanOmni1-Quad products, 
respectively. Genotype sample quality control was accomplished by monitoring sample call 
rate, sex, heterozygote and homozygote frequencies, as well as other analogous parameters 
determined by the Bead Studio software. All steps of genotyping by Illumina platform were 
performed at Scientific and Technological Park IRCCS Multimedica, Milan, Italy. 
 
Quality control (QC) filtering 
 In order to ensure robust association tests, a quality control framework was 
preformed prior of association analysis. This framework consisted of implementing filtering 
measures of call rates (by SNP and by sample), measures of SNP genotype distribution 
(Hardy Weinberg Equilibrium (HWE) test), measures of SNP allele frequencies, and 
measures of sample heterozygosities (in autosomes and sex chromosomes). 
 
 Measures of call rates (by SNP and by sample): in the Italian study, a discovery 
phase with filtering thresholds, such as 97% genotyping call rate threshold, 97% call 
rate threshold, and  >1% minor allele frequency (MAF) threshold were implemented. 
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 Measures of SNP genotype distribution (HWE test): To check for genetic deviation 
among genotypes HWE test filtering was performed.     
 The Hardy-Weinberg law states that allele frequencies in one generation can 
be used to estimate what will happen to genotype proportions in the next generations 
as long as conditions must be met:   
a. the population is large and is randomly mating, and  
b. the population has no mutations and no migration,  
the allele frequencies will not be affected in the population. Henceforth, the genotypes 
will have equal fitness, i.e., there will be no selection.  
This can be mathematically expressed by considering a biallelic autosomal 
locus with alleles A and a, with define genotype frequencies in the population 
 
P(aa) = p11;   P(aA) = p12;  P(AA) = p22 
 
p11 + p12 + p22 = 1 
 
From this genotypes, allele frequencies P(a)=p and P(A)=q are calculated by 
 
P(a) = p = p11 + 0.5 x p12 
 
P(A) = q = p22 + 0.5 x p12 
 
      p + q = 1 
 
Thus, to test that allele and genotype frequencies will not change in a population in 
successive generations, all SNPs in the control population should be tested for HWE 
tests with a given P value criterion. SNPs failing such test will be excluded from the 
analysis.  
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As comparing the HWE tests, the observed versus the expected, an inflation 
factor is calculated. This is commonly denoted as lambda (λ), which may indicate 
poor genotyping quality control and/or genetic stratification in the population.  
In the Italian study, a HWE P value threshold < 1x10-6 was used.   
 
The quality control of sample information was based on measures of sample mix-ups, 
false/cryptic relationships, and unexpected/mixed ancestry. 
 
 Measures of heterozygosity: all female samples should have similar heterozygosity 
rates on the X-chromosome SNPs to the autosomes (1-22 chromosomes); all male 
samples should have no heterozygous X-chromosome SNPs and should be typed for 
the Y-chromosome SNPs. In the Italian samples, filtering checks for high 
heterozygosity (or high homozygosity) were performed. Subjects with either high 
heterozygosity or homozygosity were excluded from the Italian study.  
 
 Measures of gender verification: all genotyped subjects were checked for gender 
verification by heterozygosity calculation of the X-chromosome SNPs; samples with 
low but non-zero X-chromosome heterozygosities, and typically with low call rate will 
be excluded from the analysis. On the other hand, samples with high call rate, and 
but low heterozygosity, their gender was corrected using the remaining X-
chromosome SNPs for female  or Y-chromosome SNPs for male gender verification, 
respectively. 
 
 Measures of share segment analysis: in order to check relationships between 
samples, detect “odd” genotype distributions, or detect sample with different origins, 
Computation of the Identity-by-State (IBS) matrix between samples in each GWA 
dataset was performed.  
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For Italian study, all analysis within this filtering check was based on IBS matrix. 
Thus, comparison of segments (or alleles) using the identically by state (IBS) method, 
by means of checking whether the alleles look identical in the population were 
conducted. IBS alleles were treated mathematically in terms of population frequency 
rather than Mendelian probability of inheritance from the defined common ancestor. 
 
 Measures of population stratification: in order to check for population admixture 
and stratification, principal components (PC) quality control was employed. This 
technique was used to detect pattern in relationships among individuals based on 
allele frequencies at small loci. The aim of using this approach was to infer a few 
underlying axes of variations (known as eigenvectors) that summarizes the allelic 
associations in the GWAS dataset. This approach was computationally efficient. 
Confounding by stratification was controlled by adjusting for genetic background and 
when testing for allelic association even at short-range.  
The difference between admixture and stratification is that admixture generates 
gametes that consist of a mosaic of segments inherited from each of the ancestral 
subpopulation, whereas stratification generates allelic associations that were 
independent of map distance. In either case, population admixture and stratification 
are often considered together because they usually occur together and because the 
two phenomena can be modeled with similar statistical methods.  
Ultimately, the goal of applying this methodology was to control for hidden 
population stratification as a confounder in genetic association studies, and to control 
for long-range association generated by admixture when undertaking fine mapping of 
a disease locus.  
 
In summary, quality control (QC) filtering resulted in the first stage: 245,033 SNPs from the 
320K array and 573 subjects, and in the second stage: 755,863 SNPs from the 1M Human-
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DUO array and 639 subjects. QC genotyped data from both chips was then merged, totaling 
857,445 SNPs and 1,212 subjects. 
 
Imputation 
In order to check for SNPs in the vicinity of the significant SNP associations, imputations to 
infer missing SNPs based on the genotypes of the typed SNPs as well as impute genotypes 
for SNPs not on the original panel were performed using build 36, release 22 HapMap CEU 
population as the reference (www.hapmap.org).  
~2.5 million SNPs were attributed (imputed) using the maximum  likelihood  method 
implemented  in MACH 1.0 software49.  Genome-wide association analyses were performed 
using genotyped and imputed data.  
 
Statistical analysis 
Genome-wide association analysis of left ventricular hypertrophy  
In the Italian study, genome-wide association analysis of left ventricular hypertrophy was 
performed using logistic regression analysis under an additive model with the ProbABEL50 
software for analyzing the genotyped and imputed SNPs. Logistic regression model was 
adjusted for sex, age, and age2.  A statistical significance threshold of P value < 5x10-7 used 
by the Wellcome Trust Case-Control study51 was employed to identify genome-wide 
associated variants. Furthermore, a suggestive P value of < 1x10-5 was used for identifying 
potential candidate variants associated with LVH. The mathematical representation of this 
model is given as follows: 
 
LVH ~ sex + age + age2 + SNP, 
 
where SNP genotypes under the additive  models were coded as AA=0; Aa=1; and aa=2.  
Note that, “a” is the coded allele and “A” is the non-coded allele.  
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Genome-wide association analysis of left ventricular mass index  
In the Italian study, genome-wide association analysis of left ventricular mass was performed 
using linear regression under an additive model using ProbABEL50 software for analyzing all 
the genotyped and imputed SNPs. Linear regression model was adjusted for sex, age, and 
age2.  A statistical significance threshold of P value < 5x10-7 used by the Wellcome Trust 
Case-Control study51 was employed to identify genome-wide associated variants. In addition, 
a suggestive P value of < 1x10-5 was used for identifying potential candidate variants 
associated with LV mass index.  
 
LVMI ~ sex + age + age2 + SNP, 
 
where SNP genotypes under the additive  models were coded as AA=0; Aa=1; and aa=2. 
Note that, “a” is the coded allele and “A” is the non-coded allele.  
 
Genomic control 
In order to correct for false-positives following GWA analyses of LVH and LVMI, a genomic 
control measure on the chi-square test statistic is computed. Thus, the chi-square test 
statistic for any candidate locus c is then corrected using the estimated inflation factor 
(lambda). For the additive model, an estimate of the inflation factor was calculated using the 
following mathematical expression: 
 
estimated lambda = median((chisq1)2, (chisq2)2, (chisq3)2 , …., (chisqN)2) / 0.456, 
 
where chisq, chi-square test statistic; N, number of SNPs tested for association;   
 
The genomic controlled chi-square test statistic is defined as: 
 
(chisqGC)2 = (chisqc)2 / estimated lambda, 
 38 
where (chisqGC)2, genomic controlled chi-square test statistic; (chisqc)2 , chi-square test 
statistic at locus c;
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RESULTS 
 
Study samples  
Table 1 shows the descriptive data of the Italian study. The mean age was 48 ± 13 years. 
Out of 730 men and 482 women, 238 men (32.60 %) and 167 women (34.64 %) were 
diagnosed with left ventricular hypertrophy. The mean left ventricular mass index (LVMI) was 
120.64 ± 19.23 g in men and 109.94 ± 16.87 g in women. The risk factor for hypertension 
was present in 754 subjects (62.21 %) and for smoking in 289 subjects (23.84 %). The mean 
SBP was 141.22 ± 22.24 mmHg, and mean DBP was 90.89 ± 13.39 mmHg. There not were 
significant differences of blood pressure traits among men and women. The mean BMI in 
men was 27.63 ± 3.34 kg/m2 in men and 26.84 ± 4.79 kg/m2 in women.  
 
Table 1. Clinical characteristics of Italian study (N=1,212) 
 Men Women Total 
Age, mean (SD), years 47.86 (12.29) 49.06 (13.67) 48.33 (12.86) 
Body mass index mean (SD), kg/m2 27.63 (3.34) 26.84 (4.79) 27.32 (3.98) 
Systolic BP mean (SD), mm Hg 141.22 (20.89) 141.21 (24.14) 141.22 (22.24) 
Diastolic BP mean (SD), mm Hg 91.46 (13.22) 90.03 (13.63) 90.89 (13.39) 
Hypertension, No. (%) 455 (62.32%) 299 (69.53%) 754 (62.21%) 
Present smoking, No. (%) 187 (25.61%) 102 (21.16%) 289 (23.84%) 
LVH, No. (%) 238 (32.60%) 167 (34.64%) 405 (33.42%) 
LVM index mean (SD) , g/m2 120.64 (19.23) 109.94 (16.87) 116.42 (19.06) 
LV, left ventricular hypertrophy defined by LVMI >116 g/m2 in men and >104 g/m2 in women; LVM, left 
ventricular mass; Absolute value (percentage), No. (%); SD, standard deviation; 
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GWAS results of left ventricular hypertrophy (LVH)  
The quantile-quantile (Q-Q) and Manhattan plots from the GWA results on LVH in the Italian 
study are illustrated in Figure 5 and Figure 6, respectively.  
 
 
Figure 5. Q-Q plot of GWAS of LVH. The Q-Q plot depicts the observed versus the expected test 
statistics under the null hypothesis of no association. The black dots denote single nucleotide 
polymorphisms (SNPs) in regions known to be associated. The lambda denoted is the inflation factor 
estimated from chisq test statistic obtained from the logistic regression on LVH. 
 
 
 
 
 
lambda=1.07 
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Figure 6. Manhattan plot displays results of the genome-wide association analysis on LVH. Shown 
are the –log10(P) of all single nucleotide polymorphisms (SNPs) sorted by position. SNPs above the 
blue solid line (lower one) represent suggestive findings at P value < 1x10-5 whereas SNPs above the 
red solid line (upper one) represent findings at P value < 1x10-8. 
 
 
 
From the genome-wide association (GWA) results on left ventricular hypertrophy (LVH), we 
identified 19 variants (shown in Table 2) at a significant value P < 5x10-7, a priori threshold 
used by the Wellcome Trust Case-Control51.  Within the 19 GWAS hits for LVH, two variants 
were identified on chromosome 1 in C1orf106 (rs6427864, P = 1.21x10-7), and in MCOLN2 
(rs1030932; P = 2.61x10-7); two nearby IGBP5 (rs13389579, P = 1.33x10-9) and in SP140 
(rs4972945, P = 2x10-9); one on chromosome 3 nearby ZNF717 (rs686591, P = 3.93x10-9); 
three on chromosome 4 in VEGFG (rs4557213, P = 9.52x10-11), in GABRB1 (rs728294, P = 
1.28x10-8), and in ADH1C (rs283410, P = 2.36x10-8); two on chromosome 6 nearby a 
pyruvate kinase pseudogene (rs93992718, P = 1.15x10-8) and in HLA-DRA (rs6911419, P = 
2.69x10-7); one on chromosome 7 in VSTM2A (rs1403237, P = 4.90x10-10); one on 
chromosome 8 nearby KCNU1 (rs7464912, P = 5.97x10-8); one on chromosome 9 in ABL1 
(rs10556171, P = 1.67x10-7); three on chromosome 11 between HEPHL1 and PANX1 
(rs4753538, P = 4.19x10-10), in ARHGEF12 (rs11217837, P = 5.54 x10-8), in SLC35C1 
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(rs7130656, P = 8.71x10-8); and two on chromosome 12 nearby KLRA1 (rs11053849, P = 
9.43x10-8 and rs10845156, P = 1.06x10-7).  
 
Table 2. Results of GWAS of left ventricular hypertrophy (LVH) at P value < 5x10-7 
SNP 
identifier Chr Position 
Gene 
(nearest genes) 
CA/ 
NCA MAF Beta s.e. P PG 
rs6427864 
 
1 
 
199,126,036 
 
C1orf106 
(GPR25, C1orf106) 
C/T 
 
0.225 
 
0.855 
 
0.156 
 
4.73E-08 
 
1.21E-07 
 
rs1030932 
 
1 
 
85,179,836 
 
MCOLN2 
(LPAR3, MCOLN3) 
C/T 
 
0.231 
 
0.760 
 
0.143 
 
1.07E-07 
 
2.61E-07 
 
rs13389579 2 217,338,593 (IGFBP5) A/G 0.435 -0.694 0.111 3.90E-10 1.33E-09 
rs4972945 
 
2 
 
230,857,341 
 
SP140 
(SP110, SP140L) 
C/T 
 
0.405 
 
0.778 
 
0.126 
 
6.03E-10 
 
2.00E-09 
 
rs686591 3 76,134,314 (ZNF717) A/G 0.378 -0.767 0.126 1.24E-09 3.93E-09 
rs4557213 
 
4 
 
177,926,127 
 
VEGFC 
(SPCS3, NEIL3) 
A/G 
 
0.492 
 
-0.675 
 
0.101 
 
2.36E-11 
 
9.52E-11 
 
rs728294 
 
4 
 
47,052,170 
 
GABRB1 
(GABRA4,COMMD8) 
A/G 
 
0.233 
 
-0.876 
 
0.149 
 
4.32E-09 
 
1.28E-08 
 
rs283410 
 
4 
 
100,483,422 
 
ADH1C 
(ADH1B, ADH7) 
A/G 
 
0.473 
 
0.655 
 
0.114 
 
8.30E-09 
 
2.36E-08 
 
rs9392718 6 5,776,566  A/G 0.233 0.929 0.158 3.86E-09 1.15E-08 
rs6911419 
 
6 
 
32,517,765 
 
HLA-DRA 
(BTNL2, HLA-DRB9) 
C/T 
 
0.241 
 
-0.803 
 
0.151 
 
1.10E-07 
 
2.69E-07 
 
rs1403237 7 54,602,061 VSTM2A C/T 0.358 -0.799 0.124 1.35E-10 4.90E-10 
rs7464912 8 36,981,063 (KCNU1) A/C 0.345 -0.684 0.122 2.23E-08 5.97E-08 
rs1056171 
 
9 
 
132,750,822 
 
ABL1 
(EXOSC2, QRFP) 
A/G 
 
0.128 
 
-1.278 
 
0.237 
 
6.67E-08 
 
1.67E-07 
 
rs2255649 10 79,013,818 KCNMA1 C/T 0.169 1.089 0.195 2.42E-08 6.45E-08 
rs4753538 11 93,490,696 (HEPHL1, PANX1) C/T 0.307 0.844 0.131 1.14E-10 4.19E-10 
rs11217837 
 
11 
 
119,737,976 
 
ARHGEF12 
(TMEM136, GRIK4) 
A/G 
 
0.304 
 
-0.726 
 
0.129 
 
2.06E-08 
 
5.54E-08 
 
rs7130656 
 
 
11 
 
 
45,789,085 
 
 
SLC35C1 
(DKFZp779M0652, 
CRY2) 
A/G 
 
 
0.370 
 
 
-0.664 
 
 
0.120 
 
 
3.33E-08 
 
 
8.71E-08 
 
 
rs11053849 12 10,571,483 (KLRA1) C/T 0.160 1.067 0.194 3.62E-08 9.43E-08 
rs10845156 12 10,567,665 (KLRA1) C/G 0.156 -1.080 0.197 4.09E-08 1.06E-07 
SNP, single nucleotide polymorphism; Chr, chromosome; CA, coded allele; NCA, non-coded allele; 
MAF, minor allele frequency; Beta, genetic effect, se, standard deviation of beta;  P, nominal P value; 
PG, adjusted P value for genomic control; 
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The regional association plots of the first top GWA hits for LVH are illustrated below as well 
as brief discussion concerning the associated genetic finding.  
 
 
Figure 7.  Regional association plot for 1q32.1. The vertical axis (on the left) shows the negative log(P 
value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region and the 
second vertical axis (on the right side) represents the recombination rate (centimorgams  per mega 
bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis shows the 
position in mega bases. Each dot represents a SNP. Genes in the region are shown below the 
horizontal axis. 
 
 
The chromosome 1 open reading frame 206 (C1orf106) is a common susceptible 
locus for complex diseases, such as Crohn’s disease, and ulcitis disease51. Its exact cause is 
unknown, but it has been shown recently that C1orf106 interacts with TEC tyrosine kinase52, 
a set of proteins involved in intracellular signaling mechanisms of cytokine receptors, 
lymphocyte surface antigens, heterotrimeric G-proteins coupled receptors, and integrin 
molecules. Furthermore, TEC tyrosine kinase proteins are key regulatory molecules in 
cardiac injury and protection as well as in physiological response to angiotensin II53. The role 
 44 
of tyrosine kinases in cardiac remodeling has been well documented. A recent study has 
shown that an TEC isoform, Bmx is implicated in angiogenesis and that is a necessary 
component of compensatory cardiac hypertrophy54.   
 
 
Figure 8. Regional association plot for 1p22.3. The vertical axis (on the left) shows the negative log(P 
value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region and the 
second vertical axis (on the right side) represents the recombination rate (centimorgams  per mega 
bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis shows the 
position in mega bases. Each dot represents a SNP. Genes in the region are shown below the 
horizontal axis. 
 
 
The mucolin 2 (MCOLN2) is a member of the Mucolilins proteins, a family of ion 
channel proteins with homology to the transient receptor potential (TRP) superfamily of 
cation channels55. These proteins play various roles in the regulation of membrane and 
protein sorting. In the heart, MCONL1 is widely expressed. Although the function of MCONL2 
is not well known and it has not been associated with any human pathology, evidence shows 
that the MCONL2 channel is functional at the plasma membrane and is characterized by a 
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significant inward rectification similar to other MCONL mutant isoforms56. Moreover, 
biochemical interactions have been observed between in homo- and hetero-multimeric 
combinations57.    
 
 
Figure 9. Regional association plot for 2q35. The vertical axis (on the left) shows the negative log(P 
value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region and the 
second vertical axis (on the right side) represents the recombination rate (centimorgams  per mega 
bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis shows the 
position in mega bases. Each dot represents a SNP. Genes in the region are shown below the 
horizontal axis. 
 
 
The insulin-like growth factor binding protein 5 (IGFBP5) is a member of the IGFBP 
family of six secreted proteins that play an important role in the regulation of insulin growth 
factors (IGF1 and IGF2). IGFBPs exhibit distinct structural and biochemical properties, 
function as carrier proteins in the circulation, and regulate insulin growth factor (IGF) 
turnover, transport, and half-life of circulating IGFs58. The functional role of IGFBP5 in the 
heart is currently unclear, but IGFBPs that are similar to IGFBP5, such as IGFBP2, have 
been shown to be involved in cardiovascular defects in targeted knockdown zebra fish 
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embryos59. Likewise, IGFBP1 has been associated with mediating hypoxia-induced growth 
and developmental retardation in embryo and adult zebra fish60-62. 
 
 
Figure 10. Regional association plot for 2q37.1. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
 
 
The SP140, a nuclear body protein, is implicated in the control of cellular 
differentiation, cell growth, and gene transcription.63, 64 The biological processes of this gene 
makes it a potential candidate for the development of LVH. SP140 is upregulated in 
response to stimuli by cytokines, such as interferons (INFs), a group of proteins involved in 
pro-inflammatory activities.  
In pathological LVH, an increase of interferons has been shown to activate 
macrophages to produce nitric oxide, which increases vascular permeability across 
hypertrophied cardiomyocytes65. Moreover, activated macrophages produced abundant 
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ACE, resulting in local increased production of angiotensin II (Ang II), the effector peptide of 
the rennin-angiotensin system (RAS) that regulates the volume and electrolyte homeostasis 
and is involved in vascular and cardiomyocyte growth66. 
 
 
 
Figure 11. Regional association plot for 4q34.3. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
 
 
The vascular endothelial growth-factor C (VEGF-C) is homologous with other 
members of the VEGF/platelet derived growth factor (PDGF) family and is a novel regulator 
of endothelia. VEGF-C is produced as a precursor protein, which is proteolitically processed, 
and binds to ligands, VEGFR-2 and VEGFR-3, inducing tyrosine autophosphorylation67, thus 
inducing myocardial vascularization during embryogenesis and in adult mouse heart68, 69. 
VEGF-C is localized in epicardial vessels70 and expression of ligand VEGFR-3 is highly 
present throughout the ventricles68. Furthermore, VEGF-C is highly expressed in 
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cardiomyocytes following at myocardial infarction, particularly around the lesion and in all 
stages of remodeling71.  
 
 
 
Figure 12. Regional association plot for 11q21. The vertical axis (on the left) shows the negative log(P 
value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region and the 
second vertical axis (on the right side) represents the recombination rate (centimorgams  per mega 
bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis shows the 
position in mega bases. Each dot represents a SNP. Genes in the region are shown below the 
horizontal axis. 
 
 
The hephaestin-like 1 (HEPHL1) is similar to the hephaestin (HEPH), a homologue of 
the ceruloplasmin (CP) gene.  Little is known about the biological functionality of the HEPHL1 
or its relationship with cardiomyocyte hypertrophy. However, the protein encoded by the 
HEPHL1 gene shares similar properties with proteins encoded by the CP and HEPHL genes, 
which are ferroxidase enzymes involved in the heart iron and copper metabolism72, 73. 
Copper reverses hypertrophic cardiomyopathy induced by pressure overload in mice model 
through VEGF/VEGF-R1 signaling pathway74, 75; whereas, iron overload in the heart leads to 
iron deposition in the myocardium leading to cardiomyopathy76.  
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The pannexin 1 (PANX1) is homologous to the invertebrate innexins, the structural 
components of gap junctions77. Pannexins and innnexins share considerable structural 
similarities, but their sequence homology is different from connexins (Cx), the typical gap 
junction proteins. PANX1, one of three in the pannexin gene family, is ubiquitously expressed 
in the body, including in the cardiomyocytes. PANX1 biological functionality relates to 
mediation of ATP release in intracellular calcium wave initiation and propagation upon 
mechanical stress (or other stimuli, such as depolarization) and release ATP to the 
extracellular medium78. Hypertrophied cardiomyocytes are characterized by multiple genetic 
changes that modify the integration of pathways utilized for energy synthesis and intracellular 
calcium homeostasis79. Moreover, in the hypertrophied heart where ischemia-conditions are 
constantly threatening host cells, contraction and relaxation patterns are modified by 
molecular mechanisms in order to meet oxygen and metabolic demands in the heart. A 
recent study has shown that PANX1 is active during ischemic-conditions in cardiac tissue80. 
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Figure 13. Regional association plot for 4q23. The vertical axis (on the left) shows the negative log(P 
value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region and the 
second vertical axis (on the right side) represents the recombination rate (centimorgams  per mega 
bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis shows the 
position in mega bases. Each dot represents a SNP. Genes in the region are shown below the 
horizontal axis. 
 
 
The alcohol dehydrogenase 1C (class 1), gamma polypeptide (ADH1C), a cytoplasmic 
protein that encodes a class I alcohol dehydrogenase, gamma subunit. ADH1C exhibits high 
activity for ethanol oxidation and metabolizes a wide variety of substrates, including other 
aliphatic alcohols, hydroxysteroids, and lipid peroxidation products (www.genecards.org). 
Functional relevant polymorphisms are found in the genes encoding class I alcohol 
dehydrogenase (ADH) isoenzymes, ADH1C and ADH1B, affecting ethanol degradation rates 
and alcohol intake in white populations81. Expression of ADH1C is found ubiquitously in the 
whole body, including the liver, kidney, skeletal muscle, lung, heart, and digestive tract.  
 
Additional variants identified at suggestive P value < 1x10-5 are given in Supplementary 
Table 1 in the Appendix.  
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GWAS results of left ventricular mass index 
The genome-wide association results for left ventricular mass index (LVMI) illustrated by the 
Q-Q plot and Manhattan plot, given in Figure 14 and Figure 15, respectively.  
 
Figure 14.  Q-Q plot of GWAS of LV mass index. The Q-Q plot depicts the observed versus the 
expected test statistics under the null hypothesis of no association. The black dots denote single 
nucleotide polymorphisms (SNPs) in regions known to be associated. The lambda denoted is the 
inflation factor estimated from chisq test statistic obtained from the linear regression on LV mass 
index. 
 
lambda=1.03 
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Figure 15. Manhattan plot displays results of the genome-wide association analysis on LV mass 
index. Shown are the –log10(P) of all single nucleotide polymorphisms (SNPs) sorted by position. 
SNPs above the blue solid line (lower one) represent suggestive findings at P value < 1x10-5 whereas 
SNPs above the red solid line (upper one) represent findings at P value < 1x10-8. 
 
 
The GWAS results for LVMI yielded no associated variant at P value < 5x10-7. However, at 
suggestive P value < 1x10-5, we identified 23 variants that were associated with LVMI as 
shown in Table 3.  
 Interestingly for this trait, the majority of suggestive findings fell within a 97.6 Kb 
region (from 208,466,275 to 208,368,666) on chromosome 1 in SYT14 and within a 3.4 Kb 
region (from 88,225,212 to 88,221,807) on chromosome 9 in the vicinity of GAS1.  
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Table 3. Results of GWAS of left ventricular mass index (LVMI) at suggestive P value < 1x10-5 
SNP 
identifier Chr Position 
Gene 
(nearest 
gene) 
CA/ 
NCA MAF Beta s.e. P PG 
rs12739243 
 
 
1 
 
 
208,368,666 
 
 
SYT14 
(C1orf107, 
C1orf133) 
C/T 
 
 
0.170 
 
 
5.783 
 
 
1.292 
 
 
7.55E-06 
 
 
9.80E-06 
 
 
rs11119421 
 
 
1 
 
 
208,387,666 
 
 
SYT14 
(C1orf107, 
C1orf133) 
A/G 
 
 
0.219 
 
 
-5.334 
 
 
1.119 
 
 
1.89E-06 
 
 
2.54E-06 
 
 
rs11119422 
 
 
1 
 
 
208,389,448 
 
 
SYT14 
(C1orf107, 
C1orf133) 
C/T 
 
 
0.219 
 
 
-5.350 
 
 
1.121 
 
 
1.83E-06 
 
 
2.46E-06 
 
 
rs7516843 
 
 
1 
 
 
208,389,552 
 
 
SYT14 
(C1orf107, 
C1orf133) 
A/G 
 
 
0.218 
 
 
-5.355 
 
 
1.122 
 
 
1.81E-06 
 
 
2.43E-06 
 
 
rs12029138 
 
 
1 
 
 
208,391,580 
 
 
SYT14 
(C1orf107, 
C1orf133) 
A/G 
 
 
0.218 
 
 
-5.360 
 
 
1.122 
 
 
1.78E-06 
 
 
2.40E-06 
 
 
rs12130989 
 
 
1 
 
 
208,394,563 
 
 
SYT14 
(C1orf107, 
C1orf133) 
A/G 
 
 
0.107 
 
 
7.711 
 
 
1.692 
 
 
5.17E-06 
 
 
6.77E-06 
 
 
rs11119423 
 
 
1 
 
 
208,395,015 
 
 
SYT14 
(C1orf107, 
C1orf133) 
C/T 
 
 
0.217 
 
 
-5.361 
 
 
1.122 
 
 
1.75E-06 
 
 
2.36E-06 
 
 
rs4537554 
 
 
1 
 
 
208,398,208 
 
 
SYT14 
(C1orf107, 
C1orf133) 
C/T 
 
 
0.217 
 
 
-5.355 
 
 
1.121 
 
 
1.77E-06 
 
 
2.38E-06 
 
 
rs4609425 
 
 
1 
 
 
208,401,689 
 
 
SYT14 
(C1orf107, 
C1orf133) 
A/G 
 
 
0.218 
 
 
5.632 
 
 
1.141 
 
 
7.92E-07 
 
 
1.09E-06 
 
 
rs1338298 
 
1 
 
208,462,685 
 
(SYT14, 
C1orf133) 
A/G 
 
0.317 
 
-4.646 
 
1.004 
 
3.69E-06 
 
4.87E-06 
 
rs1473696 
 
1 
 
208,464,175 
 
(SYT14, 
C1orf133) 
C/T 
 
0.316 
 
4.617 
 
0.994 
 
3.43E-06 
 
4.54E-06 
 
rs677520 
 
1 
 
208,466,275 
 
SYT14, 
C1orf133 
C/T 
 
0.320 
 
-4.620 
 
0.999 
 
3.74E-06 
 
4.93E-06 
 
rs656312 1 208,486,479 (SERTAD4) C/G 0.402 -4.732 0.990 1.74E-06 2.33E-06 
rs3887276 
 
 
3 
 
 
14,861,366 
 
 
FGD5 
(C3orf20, 
NR2C2) 
C/T 
 
 
0.279 
 
 
5.142 
 
 
1.132 
 
 
5.56E-06 
 
 
7.26E-06 
 
 
rs12509827 
 
4 
 
22,959,397 
 
(GBA3, 
PPARGC1A) 
A/G 
 
0.131 
 
-8.544 
 
1.852 
 
3.98E-06 
 
5.25E-06 
 
rs2074685 7 100,648,984 
ZNHIT1 
(PLOD3, C/T 0.324 -4.846 1.022 2.11E-06 2.82E-06 
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CLDN15) 
 
 
 
 
 
 
 
 
 
 
 
 
rs7860714 
 
9 
 
1,856,537 
 
(DMRT2, 
SMARCA2) 
A/G 
 
0.407 
 
-7.950 
 
1.612 
 
8.17E-07 
 
1.12E-06 
 
rs11792039 9 88,221,807 (GAS1) A/C 0.182 6.138 1.349 5.36E-06 7.01E-06 
rs11141385 9 88,222,194 (GAS1) A/G 0.191 -6.439 1.336 1.43E-06 1.94E-06 
rs11141386 9 88,223,866 (GAS1) A/T 0.187 6.386 1.336 1.75E-06 2.35E-06 
rs12377012 9 88,224,793 (GAS1) A/G 0.171 -6.291 1.362 3.88E-06 5.12E-06 
rs12375764 9 88,225,190 (GAS1) A/T 0.170 6.242 1.358 4.30E-06 5.65E-06 
rs11141387 9 88,225,212 (GAS1) A/T 0.169 -6.181 1.352 4.87E-06 6.38E-06 
SNP, single nucleotide polymorphism; Chr, chromosome; CA, coded allele; NCA, non-coded allele; 
MAF, minor allele frequency; Beta, genetic effect, se, standard deviation of beta;  P, nominal P value; 
PG, adjusted P value for genomic control; 
 
 
Regional association plots for LVMI at suggestive P value for interesting loci are illustrated 
below.  
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Figure 16. Regional association plot for 1q32.2. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
 
 
The synaptotagmin 14 (SYT14) is a member of Sypnaptotagmins, a large family of 
putative membrane trafficking proteins that are involved in various biological functions, 
including regulation of Ca2+-triggered cellular events through Ca2+-regulated membrane 
trafficking82. Microarray data indicate that SYT14 is expressed ubiquitously in the body in 
various ways, including upregulation in the atrioventricular node82. There is not direct 
relationship between SYT14 and hypertrophic cardiomyocytes; however, a homologue 
member of the Syt family, SYT1 interacts with the SNARE protein in rises of cytosolic Ca2+. 
The SNARE protein has been shown to regulate cardiac potassium channels and natriuretic 
factor secretion in cardiomyocytes, particularly during conditions of severe stress, including 
myocardial ischemia, hypoxia, and metabolic inhibition83. 
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Figure 17. Regional association plot for 9q.21.33. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
 
 
The protein encoded by the growth arrest-specific 1 (GAS1) gene is involved in 
growth suppression, preventing normal and transformed cells at G0 from traversing into the S 
phase84, 85. During cardiac morphogenesis, GAS1 is highly expressed in the endocardium 
and myocardium of the developing heart86. Recent data show that in the adult mice heart, 
GAS1 is expressed higher in the left ventricle than in any other anatomical cardiac structure 
under normal conditions, leading the authors to hypothesize that GAS1 is one of the genes 
that would be a potential regulator, playing a causal role under hypertrophic cardiomyocyte 
stimulation87 
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DISCUSSION    
 
Left ventricular hypertrophy is a heterogeneous disorder in which patients can be stratified by 
pathophysiological characteristics, i.e., expressing distinct cardiac hypertrophic phenotypes. 
Some causes of cardiac hypertrophic can be identified (as in monogenic forms), and some 
can be suspected (as in the adaptive hypertrophy for the athletic heart). Although aspects of 
the pathophysiology of cardiac hypertrophic can be identified in many patients, the molecular 
mechanisms involved in pathological LVH are not yet known. Furthermore, left ventricular 
hypertrophy encloses a vast etiologic variability, reflected by genetic and phenotypic 
heterogeneity.  
 Many studies have demonstrated that 60% of LV mass variations is heritable and that 
most likely genetic factor play a major role. However, the genetics of left ventricular 
hypertrophy is poorly understood. Moreover, the fact that the prevalence of LVH varies within 
and across populations, demonstrate that the etiology of LVH is a combination of genetic 
predispositions and environmental influencing the features manifested in the phenotype of 
LVH. As for the Mendelian forms of LVH, this only account for small percentage of all LVH 
cases in a population, leaving the remaining unaccounted for causes to be identified.  
Additionally, apart from the combination or the pooling of genetic and environmental 
factors, most plausibility there is a set of multiple gene interactions working together or 
independently at many different cellular levels (i.e., gene-gene interactions), as well as a set 
of gene influenced by environmental factors that are likely to induce epigenetic changes 
affecting DNA transcriptional activity (gene-environment interactions).  A graphical 
interpretation of these interactions can be captured by the following illustration. 
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Figure 18. Illustration of linked mechanisms involving gene-gene interactions for developing for 
possible phenotype form of LVH 
 
Thus, the genetic variations of LVH are plausibly caused by polymorphic genetic 
differences, implicating complex interactions among various genes, and interactions among 
genetic and environmental factors.  Several strategies have begun to address the genetic 
basis of left ventricular hypertrophy.  
One approach has been to seek variant candidate genes and associate them with the 
risk of LVH as it has been explained in previously. A much more advanced approach is by 
means of genome-wide association studies (GWAS), a high throughput genotyping, utilizing 
single nucleotide polymorphism (SNP) arrays having hundreds of thousands of SNPs as 
DNA markers distributed across the human genome. These markers can identify the location 
of genes that influence the susceptibility to LVH by exploiting various phenotypic forms of 
LVH or related-quantitative traits that influence the LVH phenotype, such as LV mass.  
 In this work, performing GWA analysis allowed to identify loci associated with left 
ventricular hypertension and LV mass index anywhere across the genome with more 
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certainty and without many of the hurdles and limitations encountered as in other types of 
genetic studies. Although the ability to detect a locus depends on many factors (i.e., the 
model design and assumptions, the population genetic homogeneity, the sampling bias, the 
genetic structures, the strength of the effect of each locus, the linkage disequilibrium 
between the markers tested at the locus, and the environmental factors accounted in the 
study), this study aimed to examine a small part of the vast complexity that left ventricular 
hypertrophy encompasses. From the GWA analysis on left ventricular hypertrophy (LVH) and 
left ventricular mass index (LVMI) conducted in a population study of 1,212 individuals from 
white European ancestry, 19 variants associated with LVH were identified at a P value < 
5x10-7, the pre-specified genome-wide significance threshold in the Welcome Trust Case-
Control study51. These 19 variants correspond to 12 intronic and 7 intergenic markers located 
in different genetic loci, including C1orf106, MCOLN2, IGFBP5, SP140, ZNF717, VEGFG, 
GABRB1, ADH1C, HLA-DRA, VSTM2A, KCNU1, ABL1, KCNMA1, HEPHL1, PANX1, 
ARHGEF12, SLC35C1, and KLRA1 genes. Additionally, two more other potential loci of 
interest (SYT14 and GAS1) associated with LV mass index merit to be further studied.  
 
A limitation of the study is the 62% of subjects were receiving antihypertensive 
therapy at the time of the study, which may resulted in underestimation of the role of genetic 
factors of LVH and possibly reserve the hypertrophic changes on the LV mass. Nevertheless, 
we found potential findings that need to be further validated in other cohorts as well as 
proven their functionality in animal model settings.  
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Supplementary Table 1 Results of GWAS of left ventricular hypertrophy (LVH) at suggestive P value 
< 1x10-5 
 
SNP 
identifier Chr Position 
Gene 
(nearest gene) 
CA/ 
NCA MAF Beta s.e. P PG 
rs6427864 
 
 
1 
 
 
199,126,036 
 
 
C1orf106 
(GPR25,  
C1orf106) 
C/T 
 
 
0.225 
 
 
0.855 
 
 
0.156 
 
 
4.73E-08 
 
 
1.21E-07 
 
 
rs1030932 
 
 
1 
 
 
85,179,836 
 
 
MCOLN2 
(LPAR3,  
MCOLN3) 
C/T 
 
 
0.231 
 
 
0.760 
 
 
0.143 
 
 
1.07E-07 
 
 
2.61E-07 
 
 
rs12734277 1 213,029,394 (CENPF) C/T 0.326 0.664 0.130 3.06E-07 7.01E-07 
rs12409341 
 
1 
 
169,030,050 
 
(PRRX1,  
C1orf129) 
A/G 
 
0.274 
 
-0.734 
 
0.151 
 
1.21E-06 
 
2.56E-06 
 
rs281959 1 91,514,643 HFM1 C/T 0.380 0.660 0.139 2.19E-06 4.48E-06 
rs4329494 1 190,342,868 (RGS18) C/T 0.223 0.664 0.143 3.52E-06 6.99E-06 
rs1059267 
 
 
1 
 
 
92,747,850 
 
 
EVI5 
(GFI1,  
RPL5) 
A/C 
 
 
0.208 
 
 
0.662 
 
 
0.145 
 
 
5.05E-06 
 
 
9.83E-06 
 
 
rs13389579 2 217,338,593 (IGFBP5) A/G 0.435 -0.694 0.111 3.90E-10 1.33E-09 
rs4972945 
 
 
2 
 
 
230,857,341 
 
 
SP140  
(SP110,  
SP140L) 
C/T 
 
 
0.405 
 
 
0.778 
 
 
0.126 
 
 
6.03E-10 
 
 
2.00E-09 
 
 
rs3820821 
 
2 
 
27,009,352 
 
DPYSL5  
(MAPRE3) 
C/T 
 
0.245 
 
-0.754 
 
0.146 
 
2.58E-07 
 
5.98E-07 
 
rs12694040 2 206,690,791 (NDUFS1) C/T 0.328 0.661 0.131 4.20E-07 9.45E-07 
rs3769027 
 
2 
 
135,393,505 
 
CCNT2  
(YSK4) 
C/T 
 
0.363 
 
-0.613 
 
0.123 
 
6.24E-07 
 
1.37E-06 
 
rs4853363 2 78,120,485 (CYCSP6) G/T 0.433 0.476 0.098 1.32E-06 2.77E-06 
rs10180152 2 41,821,726 (LDHAL3) A/G 0.286 -0.619 0.130 2.11E-06 4.31E-06 
rs2718443 2 193,983,293  C/T 0.199 -0.742 0.159 3.12E-06 6.24E-06 
rs1371639 2 193,979,588  A/C 0.198 0.747 0.160 3.12E-06 6.24E-06 
rs686591 3 76,134,314 (ZNF717) A/G 0.378 -0.767 0.126 1.24E-09 3.93E-09 
rs676433 3 76,116,213 (ZNF717) A/T 0.288 0.748 0.146 3.15E-07 7.21E-07 
rs9864800 3 21,783,852 (ZNF385D) C/T 0.321 0.687 0.139 8.57E-07 1.85E-06 
rs7611653 3 169,406,166 (GOLIM4) G/T 0.114 -1.227 0.255 1.45E-06 3.04E-06 
rs4685016 
 
3 
 
13,783,011 
 
(FBLN2, 
 WNT7A) 
C/T 
 
0.290 
 
0.539 
 
0.118 
 
5.11E-06 
 
9.94E-06 
 
rs4557213 
 
 
4 
 
 
177,926,127 
 
 
VEGFC 
(SPCS3,  
NEIL3) 
A/G 
 
 
0.492 
 
 
-0.675 
 
 
0.101 
 
 
2.36E-11 
 
 
9.52E-11 
 
 
rs728294 
 
4 
 
47,052,170 
 
GABRB1  
(GABRA4, 
A/G 
 
0.233 
 
-0.876 
 
0.149 
 
4.32E-09 
 
1.28E-08 
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COMMD8) 
      
rs283410 
 
 
4 
 
 
100,483,422 
 
 
ADH1C  
(ADH1B,  
ADH7) 
A/G 
 
 
0.473 
 
 
0.655 
 
 
0.114 
 
 
8.30E-09 
 
 
2.36E-08 
 
 
rs12509827 
 
4 
 
22,959,397 
 
(GBA3,  
PPARGC1A) 
A/G 
 
0.131 
 
-0.946 
 
0.189 
 
5.93E-07 
 
1.31E-06 
 
rs1364841 
 
 
4 
 
 
20,801,088 
 
 
KCNIP4 
(PACRGL, 
NCRNA00099) 
A/G 
 
 
0.427 
 
 
-0.591 
 
 
0.121 
 
 
1.01E-06 
 
 
2.15E-06 
 
 
rs6858366 
 
4 
 
162,053,730 
 
(RAPGEF2, 
FSTL5) 
C/G 
 
0.327 
 
-0.594 
 
0.129 
 
3.91E-06 
 
7.72E-06 
 
rs12641441 
 
 
4 
 
 
152,827,073 
 
 
PET112L 
(FAM160A1, 
FBXW7) 
A/G 
 
 
0.222 
 
 
0.649 
 
 
0.142 
 
 
4.67E-06 
 
 
9.13E-06 
 
 
rs7669761 
 
 
4 
 
 
152,828,754 
 
 
PET112L 
(FAM160A1, 
FBXW7) 
A/G 
 
 
0.222 
 
 
-0.649 
 
 
0.142 
 
 
4.68E-06 
 
 
9.14E-06 
 
 
rs7724224 
 
 
5 
 
 
38,310,069 
 
 
EGFLAM 
(GDNF,  
LIFR) 
A/G 
 
 
0.268 
 
 
-0.682 
 
 
0.141 
 
 
1.23E-06 
 
 
2.60E-06 
 
 
rs9392718 6 5,776,566  A/G 0.233 0.929 0.158 3.86E-09 1.15E-08 
rs6911419 
 
 
6 
 
 
32,517,765 
 
 
HLA-DRA 
(BTNL2,  
HLA-DRB9) 
C/T 
 
 
0.241 
 
 
-0.803 
 
 
0.151 
 
 
1.10E-07 
 
 
2.69E-07 
 
 
rs3115672 
 
 
6 
 
 
31,835,876 
 
 
MSH5 
(CLIC1,  
C6orf26) 
C/T 
 
 
0.345 
 
 
-0.627 
 
 
0.126 
 
 
6.90E-07 
 
 
1.51E-06 
 
 
rs2917891 6 74,644,390 (CD109) G/T 0.206 -0.725 0.157 3.71E-06 7.35E-06 
rs3012568 6 74,644,421 (CD109) G/T 0.205 0.725 0.158 4.16E-06 8.19E-06 
rs1403237 7 54,602,061 VSTM2A C/T 0.358 -0.799 0.124 1.35E-10 4.90E-10 
rs1228867 
 
7 
 
83,869,480 
 
(SEMA3A, 
HMG17P1) 
C/T 
 
0.144 
 
1.074 
 
0.209 
 
2.61E-07 
 
6.05E-07 
 
rs6965211 
 
 
7 
 
 
69,735,201 
 
 
AUTS2 
(STAG3L4, 
WBSCR17) 
C/T 
 
 
0.302 
 
 
0.647 
 
 
0.135 
 
 
1.58E-06 
 
 
3.29E-06 
 
 
rs2189349 
 
7 
 
11,309,599 
 
(PHF14,  
THSD7A) 
C/T 
 
0.400 
 
0.535 
 
0.116 
 
3.95E-06 
 
7.80E-06 
 
rs7464912 8 36,981,063 (KCNU1) A/C 0.345 -0.684 0.122 2.23E-08 5.97E-08 
rs12164144 8 43,820,269 (ASNSL1) C/T 0.165 -0.844 0.173 1.13E-06 2.39E-06 
rs4875308 
 
8 
 
4,048,012 
 
CSMD1 
(MYOM2) 
A/G 
 
0.272 
 
-0.651 
 
0.136 
 
1.70E-06 
 
3.53E-06 
 
rs1056171 
 
 
9 
 
 
132,750,822 
 
 
ABL1 
(EXOSC2,  
QRFP) 
A/G 
 
 
0.128 
 
 
-1.278 
 
 
0.237 
 
 
6.67E-08 
 
 
1.67E-07 
 
 
 63 
rs2255649 10 79,013,818 KCNMA1 C/T 0.169 1.089 0.195 2.42E-08 6.45E-08 
rs7075976 
 
10 
 
49,284,283 
 
MAPK8 
(ARHGAP22) 
A/G 
 
0.328 
 
-0.602 
 
0.118 
 
3.34E-07 
 
7.63E-07 
 
rs4918120 
 
10 
 
106,372,348 
 
(CCDC147, 
SORCS3) 
C/T 
 
0.405 
 
0.560 
 
0.113 
 
7.58E-07 
 
1.65E-06 
 
rs2813452 
 
10 
 
1,557,300 
 
ADARB2 
(C10orf109) 
C/T 
 
0.422 
 
-0.528 
 
0.113 
 
2.70E-06 
 
5.44E-06 
 
rs1324245 10 85,284,722  C/T 0.190 0.813 0.177 4.46E-06 8.74E-06 
rs10160121 10 56,836,579 (PCDH15) A/G 0.226 0.687 0.151 5.05E-06 9.83E-06 
rs4753538 11 93,490,696 
(HEPHL1,  
PANX1) C/T 0.307 0.844 0.131 1.14E-10 4.19E-10 
rs11217837 
 
11 
 
119,737,976 
 
ARHGEF12 
(TMEM136,  
GRIK4) 
A/G 
 
0.304 
 
-0.726 
 
0.129 
 
2.06E-08 
 
5.54E-08 
 
rs7130656 
 
 
11 
 
 
45,789,085 
 
 
SLC35C1 
(DKFZp779M0652, 
CRY2) 
A/G 
 
 
0.370 
 
 
-0.664 
 
 
0.120 
 
 
3.33E-08 
 
 
8.71E-08 
 
 
rs1369817 11 112,433,374 NCAM1 G/T 0.325 0.622 0.125 7.01E-07 1.53E-06 
rs2574829 11 112,433,167 NCAM1 C/G 0.214 -0.943 0.197 1.66E-06 3.45E-06 
rs11053849 12 10,571,483 (KLRA1) C/T 0.160 1.067 0.194 3.62E-08 9.43E-08 
rs10845156 12 10,567,665 (KLRA1) C/G 0.156 -1.080 0.197 4.09E-08 1.06E-07 
rs10844135 
 
12 
 
9,636,873 
 
(OVOS,  
KLRB1) 
A/C 
 
0.262 
 
-0.723 
 
0.143 
 
4.47E-07 
 
1.00E-06 
 
rs11613874 12 83,236,046  A/G 0.335 -0.594 0.123 1.36E-06 2.86E-06 
rs2255074 
 
 
12 
 
 
55,316,293 
 
 
BAZ2A 
(RBMS2,  
ATP5B) 
C/T 
 
 
0.127 
 
 
-0.977 
 
 
0.205 
 
 
1.93E-06 
 
 
3.98E-06 
 
 
rs2536929 
 
12 
 
9,572,295 
 
(DDX12, 
 KLRB1) 
A/G 
 
0.382 
 
-0.723 
 
0.152 
 
1.98E-06 
 
4.07E-06 
 
rs1795819 
 
12 
 
53,288,281 
 
(PPP1R1A,  
LACRT) 
C/T 
 
0.225 
 
-0.677 
 
0.142 
 
2.00E-06 
 
4.10E-06 
 
rs10784385 
 
12 
 
62,853,955 
 
(SRGAP1,  
C12orf66) 
G/T 
 
0.309 
 
-0.597 
 
0.126 
 
2.15E-06 
 
4.40E-06 
 
rs4466908 
 
12 
 
60,074,978 
 
(PGBD3P1, 
FAM19A2) 
A/T 
 
0.144 
 
0.835 
 
0.178 
 
2.80E-06 
 
5.64E-06 
 
rs4429133 
 
12 
 
60,074,999 
 
(PGBD3P1, 
FAM19A2) 
G/T 
 
0.146 
 
0.829 
 
0.177 
 
2.83E-06 
 
5.69E-06 
 
rs10877635 
 
12 
 
60,074,852 
 
(PGBD3P1, 
FAM19A2) 
C/T 
 
0.144 
 
0.838 
 
0.179 
 
2.89E-06 
 
5.81E-06 
 
rs1716354 
 
12 
 
53,287,894 
 
(PPP1R1A, 
GLYCAM1) 
G/T 
 
0.216 
 
0.677 
 
0.145 
 
2.90E-06 
 
5.83E-06 
 
rs1716353 
 
12 
 
53,287,858 
 
(PPP1R1A, 
GLYCAM1) 
A/G 
 
0.216 
 
-0.676 
 
0.145 
 
2.99E-06 
 
6.00E-06 
 
 64 
rs1691625 
 
12 
 
53,287,784 
 
(PPP1R1A, 
GLYCAM1) 
A/C 
 
0.216 
 
-0.675 
 
0.145 
 
3.07E-06 
 
6.14E-06 
 
rs11173956 
 
12 
 
60,075,591 
 
(PGBD3P1, 
FAM19A2) 
C/T 
 
0.140 
 
0.855 
 
0.183 
 
3.07E-06 
 
6.16E-06 
 
rs1691627 
 
12 
 
53,287,982 
 
(PPP1R1A, 
GLYCAM1) 
A/G 
 
0.203 
 
-0.677 
 
0.145 
 
3.09E-06 
 
6.19E-06 
 
rs7312486 
 
12 
 
60,076,227 
 
(PGBD3P1, 
FAM19A2) 
A/G 
 
0.139 
 
0.859 
 
0.184 
 
3.13E-06 
 
6.26E-06 
 
rs1623481 
 
12 
 
53,287,240 
 
(PPP1R1A, 
GLYCAM1) 
G/T 
 
0.216 
 
-0.674 
 
0.145 
 
3.14E-06 
 
6.28E-06 
 
rs1691626 
 
12 
 
53,287,969 
 
(PPP1R1A, 
GLYCAM1) 
A/G 
 
0.203 
 
-0.676 
 
0.145 
 
3.18E-06 
 
6.35E-06 
 
rs1400054 
 
12 
 
60,077,052 
 
(PGBD3P1, 
FAM19A2) 
A/G 
 
0.138 
 
0.863 
 
0.185 
 
3.23E-06 
 
6.44E-06 
 
rs1795821 
 
12 
 
53,287,173 
 
(PPP1R1A, 
GLYCAM1) 
C/T 
 
0.216 
 
-0.673 
 
0.145 
 
3.23E-06 
 
6.45E-06 
 
rs7967816 
 
12 
 
60,077,314 
 
(PGBD3P1, 
FAM19A2) 
C/T 
 
0.135 
 
-0.873 
 
0.188 
 
3.36E-06 
 
6.69E-06 
 
rs10492163 
 
12 
 
9,555,916 
 
(DDX12,  
KLRB1) 
A/G 
 
0.348 
 
-0.933 
 
0.201 
 
3.53E-06 
 
7.02E-06 
 
rs12578125 
 
12 
 
60,077,474 
 
(PGBD3P1, 
FAM19A2) 
A/G 
 
0.133 
 
0.881 
 
0.190 
 
3.58E-06 
 
7.10E-06 
 
rs4628751 
 
12 
 
60,078,623 
 
(PGBD3P1, 
FAM19A2) 
C/T 
 
0.132 
 
-0.885 
 
0.191 
 
3.68E-06 
 
7.29E-06 
 
rs11173961 
 
12 
 
60,078,910 
 
(PGBD3P1, 
FAM19A2) 
A/C 
 
0.131 
 
-0.889 
 
0.192 
 
3.77E-06 
 
7.47E-06 
 
rs1913927 
 
12 
 
60,080,008 
 
(PGBD3P1, 
FAM19A2) 
A/G 
 
0.128 
 
-0.902 
 
0.196 
 
4.12E-06 
 
8.10E-06 
 
rs10877640 
 
12 
 
60,079,394 
 
PGBD3P1, 
FAM19A2 
A/C 
 
0.134 
 
-0.886 
 
0.194 
 
4.92E-06 
 
9.58E-06 
 
SNP, single nucleotide polymorphism; Chr, chromosome; CA, coded allele; NCA, non-coded allele; 
MAF, minor allele frequency; Beta, genetic effect, se, standard deviation of beta;  P, nominal P value; 
PG, adjusted P value for genomic control; 
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Supplementary Figures of Regional association plots for LVH at P < 5x10-7 (as suggested by 
WTCC study 51) 
 
 
 
 
Supplementary Figure 1. Regional association plot. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
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Supplementary Figure 2. Regional association plot. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
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Supplementary Figure 3. Regional association plot. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
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Supplementary Figure 4. Regional association plot. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
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Supplementary Figure 5.  Regional association plot. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
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Supplementary Figure 6. Regional association plot. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
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Supplementary Figure 7. Regional association plot. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
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Supplementary Figure 8. Regional association plot. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
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Supplementary Figure 9. Regional association plot. The vertical axis (on the left) shows the negative 
log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated region 
and the second vertical axis (on the right side) represents the recombination rate (centimorgams  per 
mega bases) for measuring genetic linkage among all SNPs within this region. The horizontal axis 
shows the position in mega bases. Each dot represents a SNP. Genes in the region are shown below 
the horizontal axis. 
 
 
 
 
 
 74 
 
 
 
Supplementary Figure 10. Regional association plot. The vertical axis (on the left) shows the 
negative log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated 
region and the second vertical axis (on the right side) represents the recombination rate 
(centimorgams  per mega bases) for measuring genetic linkage among all SNPs within this region. 
The horizontal axis shows the position in mega bases. Each dot represents a SNP. Genes in the 
region are shown below the horizontal axis. 
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Supplementary Figures for Regional association plots for LVMI at P < 1x10-5  
 
 
 
 
Supplementary Figure 11. Regional association plot. The vertical axis (on the left) shows the 
negative log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated 
region and the second vertical axis (on the right side) represents the recombination rate 
(centimorgams  per mega bases) for measuring genetic linkage among all SNPs within this region. 
The horizontal axis shows the position in mega bases. Each dot represents a SNP. Genes in the 
region are shown below the horizontal axis. 
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Supplementary Figure 12. Regional association plot. The vertical axis (on the left) shows the 
negative log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated 
region and the second vertical axis (on the right side) represents the recombination rate 
(centimorgams  per mega bases) for measuring genetic linkage among all SNPs within this region. 
The horizontal axis shows the position in mega bases. Each dot represents a SNP. Genes in the 
region are shown below the horizontal axis. 
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Supplementary Figure 13. Regional association plot. The vertical axis (on the left) shows the 
negative log(P value) of the associated single nucleotide polymorphisms (SNPs) within the illustrated 
region and the second vertical axis (on the right side) represents the recombination rate 
(centimorgams  per mega bases) for measuring genetic linkage among all SNPs within this region. 
The horizontal axis shows the position in mega bases. Each dot represents a SNP. Genes in the 
region are shown below the horizontal axis. 
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